Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

Tanaka, Satoru; Nohara, Takehiro; Iwamoto, Mitsuhiko; Sumiyoshi, Kazuhiro; Kimura, Kosei; Takahashi, Yuko; Tanigawa, Nobuhiko

doi:10.1007/s00280-008-0877-5

Cited by 39 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microtubule associated protein (MAP) Tau binds to β-tubulin in the same place as paclitaxel and may consequently compete with this drug (15). Some studies focused on breast and gastric cancer revealed that patients with low expression of Tau protein benefit from paclitaxel therapy (16)(17)(18)(19)(20). Nevertheless, other studies, based on larger groups of breast cancer patients did not confirm these results (21,22).…”

Section: Introductionmentioning

confidence: 53%

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

Steffensen

Smoter

Waldstrøm

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. In oncology, a rational approach to identify patients who are likely to benefit from therapy, already before initiation of treatment, is urgently required. Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy. Other data suggest Tau protein expression as a predictor of clinical outcome in cancer patients treated with paclitaxel-based chemotherapy as low tau expression may render microtubules more vulnerable to paclitaxel. Therefore, the combination of ERCC1 and Tau may be a valuable predictor of sensitivity to platinum/paclitaxel treatment. The primary aim of the study was to investigate whether ERCC1 and Tau protein expression correlates with patient outcome in newly diagnosed epithelial ovarian cancer (EOC) patients. Formalin-fixed, paraffin-embedded tissue sections from 227 newly diagnosed EOC patients were used for immunohistochemical staining for ERCC1 and Tau proteins. All patients received standard first-line combination platinum and paclitaxel chemotherapy. The patients were divided in a training set of 84 patients and an independent validation cohort of 143 patients. Neither ERCC1 nor Tau expression was associated with clinical response or platinum resistance in both the training and validation sets. Patients with ERCC1-positive tumors had significantly shortened progression-free and overall survival compared to patients with ERCC1-negative tumors, p<0.00001 and p= 0.0006. In multivariate analysis ERCC1 also proved as an independent predictor of PFS and OS with HR of 3.86 and 1.98, respectively but the data could not be confirmed in the validation set. Tau expression was not associated with PFS or OS in this study. ERCC1 and Tau might serve as biomarkers of DNA repair and for paclitaxel sensitivity but the present study could not validate ERCC1 or Tau protein expression in tumors as pre-treatment tools to predict sensitivity to first-line platinum/paclitaxel chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 53%

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

Steffensen

Smoter

Waldstrøm

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Hence, among a variety of potentially relevant molecules, ERCC1 and MAP-Tau were selected because they are involved in the process of 'recovery' from the platinum and taxane cytotoxic eVect, respectively [28][29][30]. Moreover, the expression of tyrosine kinase receptors (TKRs), such as HER2, EGFR and MET, has being thoroughly investigated [31][32][33] in solid tumors, but Wndings in gastric cancer are still controversial.…”

mentioning

confidence: 99%

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

Bamias

Karina

Papakostas

et al. 2010

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

“…Finally, high RRM1 expression is predictive for poor response to gemcitabine-based therapy [24,52]. Emerging evidence suggests that reduced expression of the tau family of microtubule stabilizing proteins may predict response to paclitaxel in other tumor types, including breast, gastric, and ovarian cancers [58][59][60]. It remains to be determined whether tau expression is also a predictive marker for response to paclitaxel in NSCLC.…”

Section: Biomarkers and Treatment Selectionmentioning

confidence: 94%

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

Chang¹

2011

Lung Cancer

383

317

View full text Add to dashboard Cite

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

Abstract: Patients with tau-positive expression may derive less benefit than tau-negative from paclitaxel therapy in MBC.

Cited by 39 publications

References 20 publications

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

Contact Info

Product

Resources

About